The Initial Double-Blind Drug-Eluting Stent vs Bare-Metal Stent Study.

Phase 2

Completed

• Conditions: Coronary Artery Disease
• Interventions: Device: Bare metal Bx Velocity™; Device: Sirolimus coated Bx Velocity™

• Registration Number: NCT00233805
• Lead Sponsor: Cordis Corporation

Brief Summary

The main objective of this study is to assess the safety and effectiveness of the sirolimus coated Bx VELOCITY stent in reducing angiographic in-stent late loss in de novo native coronary lesions as compared to the bare metal Bx VELOCITY balloon-expandable stent. Both stents will be mounted on the Raptor Rapid Exchange Delivery Stent System.

Detailed Description

This is a multicenter (19 sites), prospective, randomized study. This study has a 2 arm design assessing the safety and effectiveness of the sirolimus coated BxTM VELOCITY stent to the bare metal BxTM VELOCITY stent, both mounted on the Raptorâ Rapid Exchange Stent Delivery System. A total of 220 patients will be entered in the study and will be randomized on a 1:1 basis. Patients will be randomized to the coated or uncoated BX VELOCITY stent. Therefore, neither the Investigator nor the patient will know which stent will be implanted. Patients will be followed for twelve months post-procedure, with all patients having a repeat angiography at 6 months. An ancillary study with in-stent IVUS measurements at 6 months follow-up will be performed in all patients of 6 pre-selected clinical sites. It is assumed that these sites will enroll more than 90 patients.

Study Timeline

• Study Start: 2000-08
• Study First Submitted: 2005-10-04
• Study First Submitted QC: 2005-10-05
• Study First Posted: 2005-10-06
• Study Completion: 2007-12
• Status Verified: 2008-08
• Last Update Submitted: 2008-08-05
• Last Update Posted: 2008-08-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

1. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;
2. Single treatment of de novo lesion in a coronary artery which can be appropriately covered by a study stent of 18mm in length in patients with single or multivessel disease; patients with multiple lesions can be included only if the other lesions do not require treatment;
3. Target lesion is >= 2.5 and <= 3.5mm in diameter (visual estimate);
4. Target lesion is located in a native coronary artery which can be covered by one stent (single lesion);
5. Target lesion stenosis is >50% and <100% (TIMI I) (visual estimate).

Exclusion Criteria

1. A Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the CK and CK-MB enzymes are back to normal;
2. Unprotected left main coronary disease with >=50% stenosis;
3. Have an ostial target lesion;
4. Angiographic evidence of thrombus within target lesion;
5. Calcified lesions which cannot be successfully predilated;
6. Ejection fraction <=30%;
7. Totally occluded vessel (TIMI 0 level);
8. Target lesion involves bifurcation including a side branch >=2.5mm in diameter (either stenosis of both main vessel and major branch or stenosis of just major branch) that would require side branch stenting which is likely to occur if side branch is diseased and intended to be stented;
9. Planned Direct Stenting.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Bare metal Bx Velocity™	Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
2	Sirolimus coated Bx Velocity™	Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system

Primary Outcome Measures

Name	Time	Method
Angiographic in-stent late loss as determined by Quantitative Coronary Angiography.	6 months follow-up

Secondary Outcome Measures

Name	Time	Method
In-stent mean %DS by QCA	post-procedure
In-target vessel segment MLD	6 months
In-stent MLD	6 months
Target Lesion Revascularization	6 and 12 months; or 2, 3, 4 and 5 years
Target Vessel Revascularization	6 and 12 months; or 2, 3, 4 and 5 years
Major Adverse Cardiac Events	30 days; 6 and 12 months; or 2, 3, 4 and 5 years;
Neo-intimal growth assessed by IVUS	6 months

Trial Locations

Locations (1)

Dr Marie-Claude Morice; 🇫🇷 Massy, France